Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 2,801–2,900 of 3,116
Chen, A. S., Brunetto, W. L., Canavan, M., Lipska, K. J., Richey, E. A., Wilson, M. S., Zarro, J., & Ross, J. S. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09691-4 · Cited by 1
PCSK5 promotes angiogenesis and cardiac repair after myocardial infarction
Guo, J., Ma, S., Ma, J., Liu, M., Ge, F., Wang, X., Lin, J. I. N. Y. I., Jiang, N., Lin, X., Lian, Z., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72148-7 · Cited by 1
Zheng, Y., Qin, G., Li, Z., Zhu, X., Shi, H., & Zhang, F. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1932608
He, K., Wei, Y., Zhao, H., Zhang, L., Wu, F., Liu, R., Zhang, Y., Wang, Y., Chen, H., ZENG, M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71218 · Cited by 1
Maqsood, A., Khan, A. R., Aaqil, S. I., Cheema, A. A. A., Ali, M., Jacob, J., Muhammad, N., & Siddiqi, A. K. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005191 · Cited by 2
“…cardiovascular events (MACE) were reduced by 20% in overweight/ obese individuals with pre-existing cardiovascular disease without diabetes treated with semaglutide 2.4 mg compared to placebo (6.5% vs. 8.0%; absolute risk reduction [ARR] 1.5%, number needed to treat [NNT] ≥ 67 over ∼ 4 years) [1] .”
InfluentialCastellanos, Á. M. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1014539 · Cited by 1
Evolving perspectives in personalized cardiovascular care
Attanasio, A. F., Disabato, G., Guida, G., et al. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf081
Rivera, R., Castaneda, R., Sobel, T., & Andrade, M. D. H. (2026) · Springer eBooks · doi:10.1007/978-3-032-18203-6_8 · Cited by 3
Glucagon-like-peptide 1 (GLP-1) Receptor Agonists in Rheumatologic Disease
Trinacty, J., & Rostom, K. (2025) · Canadian rheumatology today. · doi:10.58931/crt.2025.2158
Dajti, E., & Rodrigues, S. G. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17943
Lee, J. M., Kim, Y., Lee, S. Y., Kwon, W., Hwang, D., Chon, M. K., Joh, H. S., Lee, S. H., Lee, K. Y., Seo, Y. H., et al. (2026) · Journal of Cardiovascular Intervention · doi:10.54912/jci.2026.0018
Emerging Therapeutic Frontiers in Cardiology: What Does the Future Hold?
Holmes, N. (2025) · European Medical Journal · doi:10.33590/emj/scnp9535
Survivorship Challenges in Metastatic Prostate Cancer in the Era of Prolonged Survival: A Review
Garcia, C. C., Moryousef, J., Pinthus, J. H., & Leong, D. P. (2026) · Cancers · doi:10.3390/cancers18152465
“In addition, these agents improve glycemic control and several cardiometabolic risk factors, while semaglutide has also been shown to reduce major adverse cardiovascular events in individuals with overweight and established cardiovascular disease [99–102].”
Li, Q., Yang, T., Jin, G., & Zhou, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1930278
Ballerio, M., Minoretti, P., & Emanuele, E. (2026) · Clinics and Practice · doi:10.3390/clinpract16080137 · Cited by 1
Ganguly, A. K., Banerjee, S. K., Sagar, G. V. V., Singal, D. K., & Ganguly, A. (2026) · Clinical Phytoscience · doi:10.1186/s40816-026-00428-2
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025 · Cited by 1
Self-citationAre obesity drugs causing a severe complication? What the science says
Lenharo, M. (2026) · Nature · doi:10.1038/d41586-026-00552-6
Roe, B. E. (2026) · American Journal of Agricultural Economics · doi:10.1002/ajae.70049
Eisa, N., & Barood, O. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.01.001
“25,26 This suggests the cardiovascular benefits are approximately 30 times more favorable than the potential harm from NAION, even under worst-case assumptions.”
Menopause as a Metabolic Turning Point: Endocrine Mechanisms Linking Hormonal Transition and Obesity
Yanachkova, V. E. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1017242
GLP-1 drugs like Ozempic show promise for more than weight loss. But what’s science vs hype?
Joyce, P. (2026) · The Conversation · doi:10.64628/aa.y3rgpa3qr
Xiao-yu, Z., Wu, Q., Lu, H.-L., Xie, J.-J., Zhang, Y., Xu, Y., Guo, M., & Teng, F. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02163-7 · Cited by 2
“…59,352 eligible participants and intervention durations ranging from 26 to 104 weeks, were included in the systematic review and meta-analysis [8, 9, The included studies evaluated semaglutide or tirz-epatide primarily against placebo, other GLP-1 receptor agonists, or insulin-based regimens.”
Risikofaktor-Management bei polyvaskulärer Atherosklerose
Reuser, A., & Laufs, U. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2362-4893
From risk factor to therapeutic target: obesity therapy and cardiovascular outcomes
Arbel, R., & Dicker, D. (2026) · Heart · doi:10.1136/heartjnl-2026-327845
Pan, Y., Li, W.-H., Zhang, W., Ma, W., & Sun, H. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00599-x · Cited by 1
“In patients with established CVD, body mass index (BMI) ≥ 27 and no diabetes, semaglutide 2.4 mg weekly reduced cardiovascular death, nonfatal MI or nonfatal stroke, although treatment discontinuation was more frequent with semaglutide [257].”
InfluentialDifferential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
Ritsinger, V., Lagerqvist, B., Ekström, M., Hagström, E., & Norhammar, A. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag367
Shimada, H., Fukasawa, T., Mizuno, K., Okazawa, Y., Yokogawa, K., & Kawakami, K. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101760
AlAraibi, A. J., Shakeeb, F. N., Alqatta, T., Sharafeldin, A.-B. K., Dempsey, L., & Butler, A. E. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104994
Wohlfeld, C., Blas, A., Woodruff, J., Frick, M., Maciejewska, N., Patel, A., Grillo, C. A., Reagan, L. P., & Fadel, J. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.03.742612
Huang, S.-C., Cheng, W.-Y., Hou, C.-Y., Wu, J.-Y., Lai, C., & Tseng, W. (2026) · Frontiers in Urology · doi:10.3389/fruro.2026.1855180
Obesity, Sedentary Behavior, and Dyslipidemia
Nelson, A. J., & Pagidipati, N. J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.060
Chen, S.-C., Liu, K.-W., Huang, Y., Meyerowitz‐Katz, G., & Su, P. (2026) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000002132 · Cited by 2
“26 Several design features strengthen the internal consistency of these results, including longitudinal laboratory data and balancing on observed covariates.”
Incretin-based therapies: Effects on plasma lipids and potential mechanisms
Syed‐Abdul, M. M., & Lewis, G. F. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109057
The Cost of Inaction in Treating Obesity in the U.S.
Sapra, T., Chen, F., Dall, T. M., Hafida, S., Moody, A., Ferguson, C., Livingston, T., ElSayed, N. A., & Bannuru, R. R. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0011
Dhali, A., Biswas, J., Khan, F., Dahiya, D. S., & Mandal, S. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16080437
“Studies have shown cardiovascular benefit with semaglutide in obesity without diabetes, symptomatic improvement in obesity-related HFpEF, and kidney benefit in type 2 diabetes with chronic kidney disease [14–16].”
Alhazmi, A. M., Alayoubi, F., Mufti, R. E., & Albulushi, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103423
Pharmacotherapy for Obesity: Recent Evolution and Implications for Cardiovascular Risk Reduction
Maki, K. C., Kirkpatrick, C. F., Allison, D. B., & Gadde, K. M. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_13
Ahsan, M., Mazhar, S., Zafar, H., Mansoor, H., Nancy, F., Abbas, S. M., Shaikh, H., Khan, D. Z., Khan, A., Zahoor, B., et al. (2026) · Comprehensive physiology · doi:10.1002/cph4.70246
Metabolic syndrome in the post-ETI era
Litvin, M. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.12.008
Survival as a source of confounding, selection bias, and effect modification
Schooling, C. M., & Yang, G. (2026) · International Journal of Epidemiology · doi:10.1093/ije/dyag099
“In contrast, trials have increasingly shown benefits in older people of treating hypertension [20] and adiposity [21].”
Prieto, M. S., Romero-Dominguez, M., Orozco, R., Lilue, M., Lubián-López, D. M., González, S. P., Nieto, A., Coronado, P., Sánchez‐Borrego, R., Cano, A., et al. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109101
Role of Incretin Mimetics in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_4 · Cited by 1
Diagnostik und Therapie von Hyperlipidämien bei Kindern und Jugendlichen
Weigel, J. F. W., & Schwab, K. O. (2024) · Kinder- und Jugendmedizin · doi:10.1055/a-2418-3752
Adipositas und Diabetes mellitus Typ 2 (Update 2026)
Brix, J. M., Clodi, M., Harreiter, J., Hoppichler, F., Fw, K., Itariu, B.-K., Parzer, V., Resl, M., Schindler, K., Toplak, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02706-y
Pharmacotherapy (Obesity Management Medications)
Blacklock, R. M., Lim, A. Y. L., Koh, H., Miras, A. D., & Brown, A. C. (2026) · Wiley eBooks · doi:10.1002/9781394206148.mdp0070
Evolving indications for metabolic and bariatric surgery
Wills, M. V., & Corcelles, R. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.009
Trenas, A., Prieto-Laín, N., Gómez-Hernández, A. I., Velasco, M. Á. P., Bernal-López, M. R., Lopez-Carmona, M. D., de Lucas, M. D. G., Gómez‐Huelgas, R., & Perez-Belmonte, L. M. (2026) · Pharmaceuticals · doi:10.3390/ph19040583 · Cited by 1
“In patients with obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg once weekly reduced major adverse cardiovascular events by 20% and slowed the risk of kidney disease progression [23,24].”
InfluentialGlucagon-Like Peptide-1 Receptor Agonists in Managing High Stoma Output: A Scoping Review
Mao, C., Wang, A. J., & Le, K. D. R. (2026) · Journal of Surgical Research · doi:10.1016/j.jss.2026.03.080
Obésité : entre pléthore thérapeutique et questionnements nécessaires
Halimi, S. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.01.013 · Cited by 1
Obesity, incretin-based therapies, and cardiovascular disease in women
Salih, M., Sloots, Y. A. J., Hemels, M. E. W., Meems, L. M. G., Leening, M. J. G., & Ghossein‐Doha, C. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02084-0
“Additionally, studies with incretin-based therapies have demonstrated significant reduction in adverse cardiovascular events and death among patients with obesity or overweight and established CVD [14, 15].”
Merolla, A., & Rovere, P. Q. (2026) · Cardiac failure review · doi:10.15420/cfr.2026.22
Smolderen, K. G. E., Mena‐Hurtado, C., Divino, V. M., Zhao, Z., CHEN, Y., Boland, J., Song, J., Iyer, P., Knop, F. K., Nanna, M. G., et al. (2026) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2026.05.004
Xia, X., Chen, S., Tian, X., Xu, Q., Li, H., Zhang, Y., Zhang, X., Li, J., Wu, S., & Wang, A. T. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.10.022
Effects of obesity and weight loss interventions on cardiovascular diseases: A narrative review
Han, C., Hu, L., Song, L., & Guo, D. (2025) · Asian Heart Journal · doi:10.1097/ah9.0000000000000016
Mian, M. H. S., Janahi, K. A. H. A., Tayeb, A., Musaffar, F. M. M., Khalil, N., Toubah, S. H. A., Karim, A. M. A., Almarzooqi, A. M., Sayfoo, F. M., Hamadeh, A., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01888-y
“…outcomes from OAO and T2DM can be mitigated through effective multidisciplinary treatment using lifestyle interventions [9–11], medications [11], surgical options [12, 13], and, more recently, pharmacological interventions such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) [14–16].”
MIRI, M. L. B., Pereira, M. V. I. L., Barbalho, E. L., Barbosa, M. P., do Carmo, N. F., & Becchi, V. (2026) · Arquivos Catarinenses de Medicina · doi:10.63845/27vewf30
Cardiovascular Drug Access in Australia and New Zealand: New PBS and PHARMAC Listings, 2023–2025
Ciofani, J. L., Puranik, R., Ekmejian, A. A., Allahwala, U. K., Sinhal, S., James-Smith, J., Pepe, S., Lund, M., & Bhindi, R. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2026.06.001 · Cited by 3
Foster, M. W., Soueidy, A. A., Riley, J. M., Badenhausen, S. E., Naidu, S., Williams, N. N., Brailovsky, Y., Alvarez, R., Dumon, K. R., & Rame, J. E. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102674
Banerjee, M., Das, S., Deb, D., Roy, D., Narayan, P., Biswas, D., & Chatterjee, D. (2026) · Endocrine · doi:10.1007/s12020-025-04507-1
“Given their low risk of hypoglycemia and established cardiovascular benefits in obesity [33] and heart failure or chronic kidney disease [34] regardless of diabetes status, the present findings prompt consideration of a more proactive cardiovascular risk management strategy as in people with T2D,…”
Tudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 2
Key advances in secondary prevention after coronary artery bypass grafting
Elsherbini, A., Patel, S. K., Fedak, L., & Verma, S. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001333
European Society of Cardiology Congress 2024 Meeting: Heart Failure Highlights
DONALD, E. M., HAJDUCZOK, A. G., & CAMPBELL, P. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.09.001
James German and the Quest to Understand Human RECQ Helicase Deficiencies
Monnat, R. J. (2024) · Cells · doi:10.3390/cells13131077
Systemerkrankung Herzinsuffizienz
Christa, M., & Maack, C. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00677-w
Thirugnanam, A. M., Chandrakanth, & Pruthvi (2026) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2026.03.011
Progressionshemmung bei chronischer Nierenkrankheit
Weinmann-Menke, J., & Galle, J. (2026) · Die Innere Medizin · doi:10.1007/s00108-026-02145-x
“Die SELECT-Studie evaluierte Semaglu-tid bei 17.604 Patienten mit Adipositas ohne Diabetes und zeigte eine 20%ige Reduktion des primären kardiovaskulären Endpunkts(HR0,80,95%-KI0,72–0,90)sowie eine 22%ige Reduktion eines kombi-niertenNephropathie-Endpunkts(HR0,78, 95%-KI 0,63–0,96) [20].”
InfluentialConclusions and Recommendations
Schmaling, K. B., & Kaplan, R. M. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009391733.021
Cardiovascular health scores as predictors. Where to go next?
Afzal, S. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag030
Agonistas del receptor GLP-1 en el Perú: entre la innovación terapéutica y el uso indebido
Tirado, A. G. (2026) · Perspectivas en Ciencias Médicas y Biológicas · doi:10.68178/z6526419
Emerging Therapeutic Agents for Obesity and Future Perspectives
Otoda, T. (2025) · Journal of Nihon University Medical Association · doi:10.4264/numa.84.4_185
Ma, Y.-X., Lin, M., Nan, Y., Li, N.-N., Liu, B., Wang, H., Ning, S.-Y., & Zhang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1889437 · Cited by 3
“In 17, 604 patients with obesity and cardiovascular disease without diabetes, the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide (124).”
Garin, N., Carballo, D., Dash, J., Stirnemann, J., Reny, J., Vuilleumier, N., & Carballo, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341606 · Cited by 2
“Though these data are encouraging, part of the beneficial effects of GLP-1 agonists could be independent of weight loss, and these results cannot be directly extrapolated to weight loss resulting from lifestyle interventions in heart failure [33].”
Салухов, В. В., Galstyan, G. R., Неймарк, А. Е., Samoilov, V. S., Khalimov, Y. S., Karonova, T. L., & Sukhotskaia, N. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-155
Jiang, M., Zhang, F., Ren, M., Li, Z., Xie, Z., & Sun, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1841513
Alshaikh, A., Alshehri, A. A., Elbadawi, H., Aldawish, M., Abalkhail, F., Alsabaan, F., Alaqeel, M., Alotaibi, M., Aljuraibah, F., Wabel, A. A. A., et al. (2025) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2025.1612042 · Cited by 1
Gallagher, D., Spyreli, E., Calder-MacPhee, N., Crossley, K. L., Feuillâtre, C., Ivory, A., Karatas, B., Kelly, C. B., Lind, M., Osei-Asemani, E., et al. (2026) · medRxiv · doi:10.64898/2026.03.05.26347713
Obesity and Atrial Fibrillation: Therapeutic Perspective for GLP-1 Analogs
Szołkiewicz-Płatkowska, A., & Orczykowski, M. (2024) · In a good rythm · doi:10.5604/01.3001.0054.6436 · Cited by 1
Vignera, S. L., & Condorelli, R. A. (2026) · Pharmaceuticals · doi:10.3390/ph19081236 · Cited by 1
“The SELECT trial demonstrated that s.c. semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% (HR 0.80; 95% CI 0.72–0.90) in patients with pre-existing cardiovascular disease and overweight/obesity without T2DM [23].”
InfluentialShah, S., Abusafia, M., Sheashaa, H., Jadam, S., Ospina, S., Kaelber, D. C., Keen, S., Cho, L., & Desai, M. Y. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.09.016
Thérapeutiques de l’obésité et maladies cardiovasculaires
Lassen, P. B., & Aron‐Wisnewsky, J. (2025) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.12.006
Oh, J., & Choi, J. H. (2026) · Pharmaceuticals · doi:10.3390/ph19091361
“…trials in overweight and obese populations without diabetes have already shown a reduction in major adverse cardiovascular events with semaglutide [73]; what remains unresolved for OSA specifically is whether the loss of lean mass matters over years, and what happens to both weight and apnea…”
Prediabetes: Impact on cardiovascular risk and emerging therapeutic strategies
Biondi, F., Ghelardoni, S., Monti, E., Арманович, А. А., Caterina, R. D., & Madonna, R. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.121898
Therapieprinzipien bei Adipositas – was ändert sich in der aktualisierten S3-Leitlinie?
Rohmann, N., Hollstein, T., & Laudes, M. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01900-w · Cited by 1
Wang, S.-Y., Liu, X. Y., Li, Z.-M., Deng, C.-X., Chen, K., Zhuang, S.-Y., Xu, B., & Xu, T. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i1.114535
Adinolfi, G., Milia, V., Dinkov, B., & Stavreva, G. (2026) · Endocrines · doi:10.3390/endocrines7010009 · Cited by 1
“Semaglutide also improves other cardiometabolic risk factors (including blood pressure, lipid profile, and inflammatory markers) and slows the progression of chronic kidney disease [1,3,4,6,7].”
Chen, G., Zheng, H., Wang, Y., 桂曼, He, Z., Chen, Z., Wu, S. L., & Chen, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1812122
Sicouri, N., Brecher, V., Androutsopoulou, V., Brizzio, M., Zotos, P.-A., Baudo, M., & Sicouri, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197489
Guo, W., Wang, M., Shin, J., Li, F., O'Brien, E. C., Glover, L. M., Bortfeld, K., Zhao, A., McDevitt, R. C., Kalapura, C., et al. (2026) · medRxiv · doi:10.64898/2026.02.18.26346594
Bonafede, M., Rao, A., & Tchang, B. G. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01438-8
Sztefka, D., Jaunich, A., Szlachetka, K., & Zając, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.5402
“…its evidence spans multiple clinically relevant domains: symptom and functional improvement in HFpEF, kidney benefit in CKD with diabetes, and cardiovascular event reduction in obesity-related atherosclerotic disease (Kosiborod et al., 2023, 2024; Lincoff et al., 2023; Perkovic et al., 2024).”
InfluentialAhmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.51.90.102
Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease
Dod, R., Yadav, H., & Jovin, I. S. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2597772
“The SELECT trial, which focused on non-diabetic, over-weight and obese patients with cardiovascular disease showed that semaglutide reduced the risk of cardiovascular death, myocardial infarction and stroke compared to placebo [90].”
GLP-1 RAs in the heart failure field: Kill many birds with one stone
Christina, A., Andrej, B., & Şener, Y. Z. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132739
GLP-1 receptor agonists: from glycaemic control to cardio-reno-metabolic disease modification
Farmakis, D. T., Karampinos, K. I., & Filippatos, G. S. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag096
McGuigan, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01154-4
Projected Impact of Glucagon-Like Peptide-1 Adoption on 5-Year Coronary Stent UsePreprint
Rathore, S. S., Epstein, A. J., Zuk, E., & Curtis, J. P. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5368895
Disu, F., Okoro, N. L., Mochu, A. W., Martey, A. R., Shittu, S. A., Green, J. T., & Azubike, W. C. (2025) · Cureus · doi:10.7759/cureus.94373
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
